文献速递神经肿瘤

口服mTOR抑制剂依维莫司持续治疗复发性、影像学进展的1型神经纤维瘤病相关儿童低级别胶质瘤的II期研究:神经纤维瘤病临床试验联盟研究

A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.
PubMed 文献 · Neuro Oncol · 2020-01-01

这项II期前瞻性研究纳入23例影像学进展、既往含卡铂化疗的NF1相关儿童低级别胶质瘤患者,每日口服依维莫司,主要终点为48周无进展生存。22例可评估者中15例(68%)达缓解(1例完全缓解、2例部分缓解、12例疾病稳定),治疗耐受良好,无因毒性停药。

要点

  • 22例可评估患者中15例(68%)达缓解,含1例完全缓解、2例部分缓解、12例疾病稳定。
  • 15例缓解者中10例截至中位随访33个月仍无进展。
  • 治疗耐受良好,无患者因毒性终止治疗。

核心结论

  • 复发性/进展性NF1相关低级别胶质瘤患者在接受口服依维莫司治疗期间表现出显著的疾病稳定/缩小,且毒性特征耐受良好。
  • 作者认为依维莫司很适合未来在该人群中作为一线或联合治疗加以考虑。

研究设计与样本

  • 前瞻性II期临床试验,纳入影像学进展、NF1相关低级别胶质瘤且既往接受含卡铂化疗的儿童,每日口服依维莫司。
  • 共23例参与者入组,中位年龄9.4岁(范围3.2-21.6岁)。
  • 主要终点为48周无进展生存。
  • 检测全血依维莫司浓度及磷脂酰肌醇3激酶(PI3K)/mTOR通路抑制标志物,治疗期间系列MRI检查。

主要发现

  • 所有参与者初始均可评估疗效;1例患者在发生恶性外周神经鞘瘤后退出研究。
  • 22例参与者中15例(68%)达缓解,定义为肿瘤缩小(1例完全缓解、2例部分缓解)或肿瘤生长停滞(12例疾病稳定)。
  • 15例缓解者中10例仍无进展(中位随访33个月)。
  • 其余22例参与者在治疗完成时均存活。
  • 药代动力学参数和谷浓度显示明显的个体间变异;大多数参与者达到显示血单核细胞mTOR通路失活的PI3K/mTOR通路抑制标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activation of the mammalian target of rapamycin (mTOR) pathway is observed in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in this population. We evaluate the efficacy of the orally administered mTOR inhibitor everolimus for radiographically progressive NF1-associated pediatric LGGs. METHODS: Children with radiologic-progressive, NF1-associated LGG and prior treatment with a carboplatin-containing chemotherapy were prospectively enrolled on this phase II clinical trial to receive daily everolimus. Whole blood was analyzed for everolimus and markers of phosphatidylinositol-3 kinase (PI3K)/mTOR pathway inhibition. Serial MRIs were obtained during treatment. The primary endpoint was progression-free survival at 48 weeks. RESULTS: Twenty-three participants (median age, 9.4 y; range, 3.2-21.6 y) were enrolled. All participants were initially evaluable for response; 1 patient was removed from study after development of a malignant peripheral nerve sheath tumor. Fifteen of 22 participants (68%) demonstrated a response, defined as either shrinkage (1 complete response, 2 partial response) or arrest of tumor growth (12 stable disease). Of these, 10/15 remained free of progression (median follow-up, 33 mo). All remaining 22 participants were alive at completion of therapy. Treatment was well tolerated; no patient discontinued therapy due to toxicity. Pharmacokinetic parameters and pre-dose concentrations showed substantial between-subject variability. PI3K/mTOR pathway inhibition markers demonstrating blood mononuclear cell mTOR pathway inactivation was achieved in most participants. CONCLUSION: Individuals with recurrent/progressive NF1-associated LGG demonstrate significant disease stability/shrinkage during treatment with oral everolimus with a well-tolerated toxicity profile. Everolimus is well suited for future consideration as upfront or combination therapy in this patient population.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ullrich NJ, Prabhu SP, Reddy AT, et al. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 2020. PMID: 32236425. doi:10.1093/neuonc/noaa071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。